These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 39206747)

  • 1. Characteristics of Patients With Atherosclerotic Cardiovascular Disease in Belgium and Current Treatment Patterns for the Management of Elevated LDL-C Levels.
    Maury E; Brouyère S; Jansen M
    Clin Cardiol; 2024 Sep; 47(9):e24330. PubMed ID: 39206747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unused potential of lipid-lowering therapy in very high-risk patients with atherosclerotic cardiovascular disease. A retrospective data analysis.
    Pohl SB; Engelbertz C; Reinecke H; Malyar NM; Meyborg M; Brix TJ; Varghese J; Gebauer K
    Nutr Metab Cardiovasc Dis; 2024 Jul; 34(7):1670-1680. PubMed ID: 38664125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
    Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort.
    Lahoz R; Seshagiri D; Electricwala B; Achouba A; Ding Y; Heo JH; Cristino J; Studer R
    Curr Med Res Opin; 2024 Jan; 40(1):15-25. PubMed ID: 37941428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and predictors of cholesterol target attainment in patients with stable coronary heart disease in Belgium: results from the Dyslipidemia International Study II (DYSIS II
    Hermans MP; Gevaert S; Descamps O; Missault L; Gillot B; De Keyzer D; Lautsch D; Brudi P; Ambegaonkar B; Vyas A; Horack M; Gitt A
    Acta Clin Belg; 2019 Dec; 74(6):399-404. PubMed ID: 30355016
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.
    van de Borne P; Peeters A; Janssens L; Leone A; Lemmens R; Verhaegen A; De Meulemeester M; Balthazar Y; Heijmans S; Calozet Y; Paquot N; Carlier S; Hemelsoet D; Bray S; Ray KK
    Acta Cardiol; 2024 Feb; 79(1):20-29. PubMed ID: 35442151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and LDL-C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT-DYS study.
    Gavina C; Seabra-Carvalho D; Aguiar C; Anastassopoulou A; Teixeira C; Ruivo JA; Almeida É; Luz-Duarte L; Corte-Real A; Canelas-Pais M; Taveira-Gomes T
    Clin Cardiol; 2024 Jan; 47(1):e24183. PubMed ID: 37933175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS).
    Devroey D; Radermecker RP; Van der Schueren BJ; Torbeyns B; Jaken RJ
    Int J Clin Pract; 2014 Feb; 68(2):180-7. PubMed ID: 24308644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and Low-Density Lipoprotein Cholesterol Management in Patients Diagnosed With Clinical Atherosclerotic Cardiovascular Disease in Alberta.
    Chen G; Farris MS; Cowling T; Colgan SM; Xiang P; Pericleous L; Rogoza RM; Tai MH; Anderson T
    Can J Cardiol; 2019 Jul; 35(7):884-891. PubMed ID: 31292087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
    Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B
    Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial.
    Shah NN; Ghazi L; Yamamoto Y; Kumar S; Martin M; Simonov M; Riello Iii RJ; Faridi KF; Ahmad T; Wilson FP; Desai NR
    Circ Cardiovasc Qual Outcomes; 2024 May; 17(5):e010335. PubMed ID: 38634282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C.
    Katzmann JL; Sorio-Vilela F; Dornstauder E; Fraas U; Smieszek T; Zappacosta S; Laufs U
    Clin Res Cardiol; 2022 Mar; 111(3):243-252. PubMed ID: 32949286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia.
    Menzin J; Aggarwal J; Boatman B; Yu J; Stern K; Harrison DJ; Patel JG
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1270-1276. PubMed ID: 29172973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.